Fredag 22 November | 06:38:16 Europe / Stockholm

Prenumeration

Kalender

Tid*
2025-01-29 08:30 Bokslutskommuniké 2024
2024-11-08 - Extra Bolagsstämma 2024
2024-10-29 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-28 - Årsstämma
2024-05-17 - X-dag ordinarie utdelning ZICC 0.00 SEK
2024-04-29 - Kvartalsrapport 2024-Q1
2024-01-26 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-06-21 - X-dag ordinarie utdelning ZICC 0.00 SEK
2023-06-20 - Årsstämma
2023-04-26 - Kvartalsrapport 2023-Q1
2023-01-27 - Bokslutskommuniké 2022
2022-10-27 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-04-29 - X-dag ordinarie utdelning ZICC 0.00 SEK
2022-04-28 - Kvartalsrapport 2022-Q1
2022-04-28 - Årsstämma
2022-02-17 - Bokslutskommuniké 2021
2022-01-18 - Extra Bolagsstämma 2022
2021-10-28 - Kvartalsrapport 2021-Q3
2021-08-26 - Kvartalsrapport 2021-Q2
2021-04-28 - X-dag ordinarie utdelning ZICC 0.00 SEK
2021-04-27 - Årsstämma
2021-04-23 - Kvartalsrapport 2021-Q1
2021-02-11 - Bokslutskommuniké 2020
2020-11-06 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-06-17 - X-dag ordinarie utdelning ZICC 0.00 SEK
2020-06-16 - Årsstämma
2020-04-17 - Kvartalsrapport 2020-Q1
2020-02-13 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-08-21 - Kvartalsrapport 2019-Q2
2019-05-20 - Årsstämma
2019-05-10 - X-dag ordinarie utdelning ZICC 0.00 SEK
2019-05-09 - Kvartalsrapport 2019-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Ziccum är ett svenskt läkemedelsbolag som utvecklar nya beredningar av biologiska läkemedel. Med bolagets patenterade teknologi LaminarPace utvecklas torra beredningsformer av produkter som i nuläget finns i vätskeform. Störst verksamhet återfinns runtom Norden, samt utöver huvudverksamheten erbjuder bolaget diverse relaterade produkter. Bolagets huvudkontor ligger i Lund.
2024-04-03 16:32:00

Ziccum is reorganizing its administrative functions, due to the increased amount of business dialogues and to perform financial reporting in a more streamlined fashion. Two new roles of Business & Project Manager and a business-oriented, junior Financial Manager are introduced while the CFO role is eliminated.

As Ziccum is progressing generating strong data for LaminarPaceTM treatment of mRNA/LNP modalities, the industry interest is growing and business dialogues are increasing in number, requiring more resources to be well taken care of. The successful licensing business model, based on technology licensing and including paid feasibility programs, has been rewarded by agreements with leading Pharma and Biotech partners requiring project execution in addition to the internal development projects. The company is therefore recruiting for a position as Business & Project Manager, where final candidates with excellent credentials have been selected.

In parallel, a more efficient solution to perform company public reporting has been established by setting up limited consultant support from the Ziccum accounting partner, Ekonomistubben. The new organizational set-up is also complemented by the hiring of a junior Finance Manager with business profile, who will have an active role in partner interaction as well as investor relations and soft funding. Ziccum has recruited a young US-educated talent with advisory background in New York plus London, Christo Vassilev.

As a consequence of the reorganization the position as Chief Financial Officer is eliminated and the current person holding this position, Johny Humaloja, has been given notice to leave Ziccum. He will maintain his role for a smooth and efficient handover, to ensure good adherence to the Nasdaq First North requirements.

Ziccum CEO Ann Gidner: “This carefully planned re-organization is strengthening the Ziccum team and will contribute to the successful continued development of the company and its business, better harnessing the significant industry interest, while keeping spending at an optimal level for Ziccum’s current development stage. We have succeeded very rapidly building our reputation in international industry and we are delighted to strengthen our team accordingly with talented candidates, giving Christo a very warm welcome. We are thanking Johny for the efforts spent at Ziccum.”